Skip to main content

Table 3 Univariate and multivariate Cox regression survival analysis of breast cancer-specific survival (CSS) and time to recurrence (TTR) as a function of Nuc-Stat5a in breast cancer patients treated with antiestrogen monotherapy (Materials V and VI)

From: Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes

Material V CSS (n= 73)   Multivariate adjusted (Cox) Univariate unadjusted (Cox)
Variable n Hazard ratio (95% CI) Pvalue Hazard ratio (95% CI) Pvalue
Grade 1 17 1 - 1 -
  2 43 3.42 (0.42 to 27.87) 0.251 3.74 (0.46 to 30.52) 0.218
  3 13 2.60 (0.23 to 29.30) 0.438 3.32 (0.30 to 36.66) 0.327
Size < 2 cm 40 1 - 1 -
  ≥2 to ≥5 cm 33 4.29 (0.86 to 21.38) 0.075 5.79 (1.23 to 27.26) 0.026
Stat5a Low (0) 9 4.19 (1.13 to 15.48) 0.032 6.73 (1.88 to 24.05) 0.003
  High (> 0) 64 1 - 1 -
Global test for PH assumption: χ2(3) = 1.67; P = 0.64.
Material V TTR ( n = 73)   Multivariate adjusted (Cox) Univariate unadjusted (Cox)
Variable n Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Grade 1 17 1   1  
  2 43 1.20 (0.30 to 4.81) 0.794 1.27 (0.32 to 5.04) 0.729
  3 13 1.59 (0.31 to 8.22) 0.581 1.87 (0.37 to 9.39) 0.448
Size < 2 cm 40 1   1  
  ≥2 to ≥5 cm 33 1.63 (0.49 to 5.43) 0.429 2.24 (0.73 to 6.86) 0.158
Stat5a Low (0) 9 4.27 (1.20 to 15.19) 0.025 5.08 (1.52 to 17.01) 0.008
  High (> 0) 64 1   1  
Global test for PH assumption: χ2(3) = 1.47; P = 0.69.
Material VI CSS ( n = 55)   Multivariate adjusted (Cox) Univariate unadjusted (Cox)
Variable n Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Grade 1 8 1 - 1 -
  2 28 3.48 (0.91 to 13.31) 0.068 1.11 (0.36 to 3.41) 0.855
  3 19 2.83 (0.65 to 12.28) 0.164 2.25 (0.73 to 6.91) 0.158
Size < 2 cm 24 1 - 1 -
  2 to ≥5 cm 26 3.51 (1.26 to 9.74) 0.016 4.22 (1.76 to 10.13) 0.001
  ≥5 cm 5 8.54 (1.92 to 37.94) 0.005 6.94 (2.01 to 24.00) 0.002
LN status Neg 29 1 - 1 -
  Pos 26 4.72 (1.90 to 11.74) < 0.001 4.30 (1.98 to 9.33) < 0.001
ER/PR status Neg 8 1 - 1 -
  Pos 47 0.73 (0.22 to 2.38) 0.597 0.37 (0.16 to 0.86) 0.021
Her2 status Neg 48 1 - 1 -
  Pos 7 2.87 (0.92 to 8.96) 0.070 3.07 (1.23 to 7.63) 0.016
Stat5a Low (< 1,454) 16 4.95 (1.87 to 13.06) 0.001 2.75 (1.33 to 5.69) 0.006
  High (≥1,454) 39 1 - 1 -
Global test for PH assumption: χ2(6) = 3.19; P = 0.78.
Material VI TTR ( n = 55)   Multivariate adjusted (Cox) Univariate unadjusted (Cox)
Variable n Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Grade 1 8 1 - 1 -
  2 28 1.17 (0.37 to 3.72) 0.794 0.87 (0.31 to 2.41) 0.783
  3 19 1.24 (0.33 to 4.68) 0.746 1.98 (0.71 to 5.55) 0.191
Size < 2 cm 24 1 - 1 -
  2 to ≥5 cm 26 3.38 (1.30 to 8.80) 0.013 3.75 (1.67 to 8.43) 0.001
  ≥5 cm 5 8.17 (2.26 to 29.50) 0.001 6.91 (2.27 to 21.06) < 0.001
LN status Neg 29 1 - 1 -
  Pos 26 3.46 (1.57 to 7.64) 0.002 3.42 (1.67 to 7.01) < 0.001
ER/PR status Neg 8 1 - 1 -
  Pos 47 0.51 (0.17 to 1.48) 0.214 0.30 (0.13 to 0.68) 0.004
Her2 status Neg 48 1 - 1 -
  Pos 7 3.35 (1.13 to 9.93) 0.029 3.06 (1.24 to 7.56) 0.015
Stat5a Low (< 1,454) 16 2.14 (0.89 to 5.12) 0.087 2.15 (1.06 to 4.35) 0.033
  High (≥1,454) 39 1 - 1 -
  1. Global test for PH assumption: χ2(6) = 4.67; P = 0.59. CI, confidence interval; ER/PR status, estrogen or progesterone receptor positive; HR, hazard ratio; LN status, lymph node status.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us